Loading...
XSWX
HBMN
Market cap1.71bUSD
Dec 05, Last price  
206.00CHF
1D
0.24%
1Q
15.34%
Jan 2017
108.08%
IPO
151.22%
Name

HBM Healthcare Investments AG

Chart & Performance

D1W1MN
XSWX:HBMN chart
P/E
74.23
P/S
61.53
EPS
2.78
Div Yield, %
3.64%
Shrs. gr., 5y
-0.44%
Rev. gr., 5y
-34.54%
Revenues
22m
+650.20%
136,416,0000213,517,000110,246,00090,054,000-34,908,000-18,674,00070,385,000356,782,000260,907,00025,930,000139,986,000118,653,000213,069,000186,189,000766,308,000-76,500,000-144,897,0002,982,00022,371,000
Net income
19m
P
144,825,300150,896,000222,304,000-312,880,00066,033,000-56,382,000-22,169,00067,005,000353,522,000257,511,00023,089,000136,772,000115,874,000209,067,000182,698,000756,271,000-78,031,000-146,318,000-1,083,00018,542,000
CFO
-2m
L+38.48%
-58,735,00011,551,00038,886,00026,737,000-16,424,000-17,171,000-14,069,00067,005,000353,522,000257,511,00023,089,000136,772,000115,874,000-2,852,000-4,158,000-3,226,000-10,197,000-1,288,000-1,705,000-2,361,000
Dividend
Aug 07, 20247.5 CHF/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

HBM Healthcare Investments AG specializes in fund of funds and direct investments in middle market and mature companies. The fund prefers to invest in start up, early stage, mid stage, mid venture, late venture, and late stage private companies, unlisted emerging companies, small cap public companies, buyouts, growth capital, and private investment in public equities (PIPES). Within fund of funds, it invests in venture capital funds. It also seeks to finance spin-offs of product lines or departments from larger corporations and the expansion or restructuring of established companies, seed stages, venture capital, expansion capital stages, spin-offs, and buyouts. The fund prefers to invest in the private and public companies in the healthcare sector with a focus on human medicine, drugs, pharma , biopharma, biotechnology, diagnostics, medical technology, and related industries. It seeks to make initial investments in companies whose primary products are in clinical development or the immediately preceding stage. The fund typically invests globally with a focus on Asia Pacific, Asia, North America, and Europe. In case of public companies, it focuses on those which originate from its private portfolio. The fund increases its investment in portfolio companies by participating in a follow-on financing or after the portfolio company's IPO. It may acquire majority participations in portfolio companies, usually takes a seat on the portfolio company's Board of Directors, and largely makes equity investments but may also invest through other instruments including convertible bonds, debt securities, structured products, and derivatives. The fund exits its portfolio companies through trade sale or IPO.
IPO date
Feb 14, 2008
Employees
Domiciled in
CH
Incorporated in
CH

Valuation

Title
CHF in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑032024‑032023‑032022‑032021‑032020‑032019‑032018‑032017‑032016‑03
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT